Sun Pharma to Acquire Organon in $11.75 Billion Deal

Sun Pharmaceutical Industries has agreed to acquire US-based Organon & Co. for $11.75 billion, marking one of the largest overseas deals by an Indian pharma company. The move instantly scales Sun Pharma's footprint in two high-growth areas: women's health and biosimilars, where Organon already has established commercial infrastructure across global markets. Organon was spun off from Merck in 2021 and carries a portfolio of branded, biosimilar, and established medicines sold in more than 140 countries. The deal gives Sun Pharma immediate access to that distribution reach rather than building it organically, which typically takes years and carries higher execution risk. For Sun Pharma, whose revenue is already skewed toward specialty and branded generics, Organon adds a meaningful innovative medicines layer. The combined entity would rank among the largest diversified pharma players globally. Watch for details on deal financing, debt structure, and regulatory clearances across multiple jurisdictions, all of which will shape how markets price the transaction in the near term.